Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 415 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines July 15, 2020 Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 Load more HOT NEWS Panitumumab Added to Infusional Fluorouracil Plus Leucovorin May Be a Reasonable... Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas Junk food marketing restrictions: so near and yet so far FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer
